Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Fatih Sultan Mehmet Training and Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03757650CT.gov THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morbid Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bismuth Salicylate (this asset) | Fatih Sultan Mehmet Training and Research Hospital | Approved | BB · 65 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Chenodeoxycholic Acid | Hvidovre University Hospital | P4 | BBB |
| Ramifentanyl | Hospital dos Lusíadas | P4 | BBB |
| Colesevelam | Hvidovre University Hospital | P4 | BBB |
| Propofol | G.Gennimatas General Hospital | P4 | BBB |
| Amoxicillin | Fatih Sultan Mehmet Training and Research Hospital | P4 | BBB |
| Semaglutide | Zuyderland Medisch Centrum | P4 | BBB |
| Dexmedetomidine | Cairo University | P4 | BB |
+42 more in the Morbid Obesity cohort
Other indications for Bismuth Salicylate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Helicobacter Pylori Infection, Susceptibility To | — | P4 | BB · 68 |
| Lymphoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bismuth Salicylate in Morbid Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bismuth-salicylate-morbid-obesity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →